Assembly Biosciences, Inc.

ASMB ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $58.5M $38.3M $19.8M $52.4M $45.6M $59.4M $46.7M $41.5M
Accounts Receivable $974.0K $0 $43.0K $944.0K $336.0K $1.2M $3.4M $2.4M
Inventory
Total Current Assets $254.5M $115.5M $133.8M $97.0M $154.2M $224.5M $282.8M $222.5M
Property, Plant & Equipment $221.0K $284.0K $385.0K $743.0K $1.1M $1.6M $1.8M $557.0K
Goodwill $12.6M $12.6M $12.6M
Intangible Assets (Excl. Goodwill)
Total Assets $257.6M $119.2M $136.8M $101.8M $191.1M $283.3M $339.9M $268.0M
Liabilities
Accounts Payable $1.2M $585.0K $461.0K $2.5M $2.7M $4.6M $1.7M $3.7M
Total Current Liabilities $48.8M $47.8M $39.2M $16.3M $16.1M $24.4M $24.4M $18.5M
Long-Term Debt
Total Liabilities $50.8M $85.8M $95.7M $19.1M $22.1M $42.7M $66.7M $57.4M
Stockholders' Equity
Retained Earnings $-832.0M $-825.9M $-785.7M $-724.5M $-631.4M $-501.6M $-439.4M $-341.8M
Total Stockholders' Equity $206.8M $33.4M $41.1M $82.7M $168.9M $240.6M $273.2M $210.7M
← Newer Page 1 of 2 Older →